American Century Companies Inc Nurix Therapeutics, Inc. Transaction History

American Century Companies Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$12.02 - $21.3 $600,302 - $1.06 Million	-49,942 Reduced 83.15%	10,124 $211,000
Q1 2024 May 14, 2024	BUY	$7.77 - $15.66 $130,349 - $262,712	16,776 Added 38.75%	60,066 $882,000
Q4 2023 Feb 13, 2024	BUY	$4.25 - $10.71 $183,982 - $463,635	43,290 New	43,290 $446,000
Q3 2023 Nov 13, 2023	BUY	$7.86 - $10.08 $61,119 - $78,382	7,776 Added 33.72%	30,839 $242,000
Q2 2023 Aug 14, 2023	BUY	$8.7 - $13.28 $91,619 - $139,851	10,531 Added 84.03%	23,063 $230,000
Q1 2023 May 11, 2023	BUY	$8.56 - $13.26 $18,832 - $29,172	2,200 Added 21.29%	12,532 $111,000
Q4 2022 Feb 13, 2023	BUY	$9.86 - $14.59 $101,873 - $150,743	10,332 New	10,332 $113,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $923M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

Stay updated on American Century Companies Inc with notifications on news.